Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
Ramesh K. Ramanathan, Daniel D. Von Hoff, Ferry Eskens, George Blumenschein, Donald Richards, Isabelle Genvresse, Susanne Reschke, Camille Granvil, Adam Skubala, Carol Peña, Klaus Mross
Dive into the research topics of 'Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer'. Together they form a unique fingerprint.